Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
biote Corp. stock logo
BTMD
biote
$1.96
-6.7%
$2.16
$1.27
$4.75
$78.92M1.65207,244 shs391,958 shs
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
$2.47
-0.8%
$2.83
$2.20
$8.30
$19.90M0.52152,321 shs78,766 shs
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$0.41
-5.4%
$0.79
$0.38
$2.30
$82.01M1.584.81 million shs2.42 million shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$6.65
+6.7%
$6.41
$3.90
$15.00
$78.60M0.69897,586 shs172,510 shs
7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
biote Corp. stock logo
BTMD
biote
-6.67%-13.27%+2.08%+48.48%-52.66%
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-0.80%-11.47%-20.32%-8.52%-68.89%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-5.75%-1.80%-53.58%-47.68%-80.93%
Lifevantage Corporation stock logo
LFVN
Lifevantage
+6.74%+3.74%-4.04%+54.65%-47.18%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
biote Corp. stock logo
BTMD
biote
$1.96
-6.7%
$2.16
$1.27
$4.75
$78.92M1.65207,244 shs391,958 shs
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
$2.47
-0.8%
$2.83
$2.20
$8.30
$19.90M0.52152,321 shs78,766 shs
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$0.41
-5.4%
$0.79
$0.38
$2.30
$82.01M1.584.81 million shs2.42 million shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$6.65
+6.7%
$6.41
$3.90
$15.00
$78.60M0.69897,586 shs172,510 shs
7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
biote Corp. stock logo
BTMD
biote
-6.67%-13.27%+2.08%+48.48%-52.66%
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-0.80%-11.47%-20.32%-8.52%-68.89%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-5.75%-1.80%-53.58%-47.68%-80.93%
Lifevantage Corporation stock logo
LFVN
Lifevantage
+6.74%+3.74%-4.04%+54.65%-47.18%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
biote Corp. stock logo
BTMD
biote
2.50
Moderate Buy$2.7540.31% Upside
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
2.50
Moderate Buy$11.00345.34% Upside
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
2.00
Hold$2.50509.76% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
2.00
Hold$5.00-24.81% Downside

Current Analyst Ratings Breakdown

Latest CLRB, BTMD, HRTX, and LFVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/15/2026
biote Corp. stock logo
BTMD
biote
UpgradeStrong-Buy
6/3/2026
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
Lower Price TargetBuy$2.00
6/2/2026
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
DowngradeBuyHold
5/28/2026
biote Corp. stock logo
BTMD
biote
UpgradeSell (D)Sell (D+)
5/26/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
UpgradeHold (C-)Hold (C)
5/15/2026
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
Initiated CoverageBuy
5/13/2026
biote Corp. stock logo
BTMD
biote
DowngradeSell (D+)Sell (D)
5/11/2026
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
Reiterated RatingBuy
5/7/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
DowngradeBuyHold$5.00
5/5/2026
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
Reiterated RatingBuy$11.00
5/4/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
DowngradeHold (C)Hold (C-)
(Data available from 6/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
biote Corp. stock logo
BTMD
biote
$192.22M0.38$0.54 per share3.62($1.40) per share-1.40
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/AN/AN/AN/A$1.89 per shareN/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$154.90M0.50N/AN/A$0.07 per share5.86
Lifevantage Corporation stock logo
LFVN
Lifevantage
$228.53M0.37$1.17 per share5.67$2.75 per share2.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
biote Corp. stock logo
BTMD
biote
$27.05M$0.444.453.70N/A8.29%-25.72%15.12%8/5/2026 (Estimated)
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-$21.79M-$6.66N/AN/AN/AN/A-349.24%-153.18%8/13/2026 (Estimated)
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$20.19M-$0.18N/AN/AN/A-20.53%-7,747.30%-8.94%8/11/2026 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$9.81M$0.4514.7810.23N/A2.94%23.89%12.47%9/3/2026 (Estimated)

Latest CLRB, BTMD, HRTX, and LFVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2026Q1 2026
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-$1.8850-$1.33+$0.5550-$1.33$8.00 millionN/A
5/11/2026Q1 2026
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$0.03-$0.04-$0.01-$0.04$36.72 million$34.71 million
5/6/2026Q1 2026
biote Corp. stock logo
BTMD
biote
$0.09$0.06-$0.03$0.06$46.02 million$44.94 million
5/6/2026Q3 2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.12-$0.04$0.11$47.77 million$43.72 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
biote Corp. stock logo
BTMD
biote
N/AN/AN/AN/AN/A
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/AN/AN/AN/AN/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.203.01%N/A44.44%3 Years

Latest CLRB, BTMD, HRTX, and LFVN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/27/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.052.12%6/1/20266/1/20266/15/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
biote Corp. stock logo
BTMD
biote
N/A
1.29
0.58
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/A
1.90
1.90
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
17.51
2.53
1.51
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.96
1.04

Institutional Ownership

CompanyInstitutional Ownership
biote Corp. stock logo
BTMD
biote
21.68%
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
16.41%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
80.01%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%

Insider Ownership

CompanyInsider Ownership
biote Corp. stock logo
BTMD
biote
32.40%
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
2.58%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
6.10%
Lifevantage Corporation stock logo
LFVN
Lifevantage
21.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
biote Corp. stock logo
BTMD
biote
19437.58 million25.41 millionNot Optionable
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
107.99 million7.79 millionNo Data
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
300189.28 million177.73 millionOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.62 million9.85 millionOptionable

Recent News About These Companies

Lifevantage (LFVN) Stock Forecast & Price Target
LFVN Share News Today
Lifevantage Stock Price History
LifeVantage (LFVN) Q3 2026 Earnings Transcript
LifeVantage Declares Quarterly Dividend
LifeVantage Q3 2026 earnings preview

New MarketBeat Followers Over Time

Media Sentiment Over Time

biote stock logo

biote NASDAQ:BTMD

$1.96 -0.14 (-6.67%)
Closing price 06/25/2026 04:00 PM Eastern
Extended Trading
$1.96 0.00 (0.00%)
As of 06/25/2026 05:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

Cellectar Biosciences stock logo

Cellectar Biosciences NASDAQ:CLRB

$2.47 -0.02 (-0.80%)
Closing price 06/25/2026 04:00 PM Eastern
Extended Trading
$2.51 +0.04 (+1.66%)
As of 06/25/2026 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Heron Therapeutics stock logo

Heron Therapeutics NASDAQ:HRTX

$0.41 -0.02 (-5.38%)
Closing price 06/25/2026 04:00 PM Eastern
Extended Trading
$0.41 0.00 (0.00%)
As of 06/25/2026 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$6.65 +0.42 (+6.74%)
Closing price 06/25/2026 04:00 PM Eastern
Extended Trading
$6.54 -0.11 (-1.65%)
As of 06/25/2026 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.